For those interested the surgeon is Shigeyuki Ozaki, MD, PHD, Department of Cardiac Surgery Toho University, Tokyo Japan.
Shigeyuki Ozaki is one of Asia's leading cardiac surgeons and has published numerous papers on heart valve reconstructions and would be considered by any measure an opinion maker and leader in this field.
Admedus appear to be collecting at a steady rate leaders and opinion makers across the world in the fields of CHD surgery and heart valve reconstructions confirming what they said in their previous ASX release that they are on the way to becoming the gold standard technology for these surgeries.
One of these markets is worth hundreds of millions of $, the other billions of $. A bright future lies ahead.
Ann: Admedus to showcase CardioCel at EACTS Annual Meeting, page-76
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |